TherapeuticsMD reported second quarter 2026 financial results showing net income from continuing operations of $164 thousand, down from $545 thousand in the prior year period. License revenues decreased to $869 thousand from $952 thousand, while total operating expenses rose slightly by 2.3% to $1.7 million due to higher general and administrative costs and patent write-offs. The company holds $9.2 million in cash and continues to evaluate strategic alternatives, including potential acquisitions or asset sales. TherapeuticsMD operates as a pharmaceutical royalty company that collects royalties from licensees rather than engaging in direct research or commercial operations.